Skip to main content
Carna Biosciences, Inc. logo

Carna Biosciences, Inc. — Investor Relations & Filings

Ticker · 4572 ISIN · JP3220550002 T Manufacturing
Open in API
Filings indexed 77 across all filing types
Latest filing 2024-03-27 Governance Information
Country JP Japan
Listing T 4572

About Carna Biosciences, Inc.

https://www.carnabio.com/

Carna Biosciences, Inc. is a clinical-stage biopharmaceutical company specializing in the discovery and development of small molecule kinase inhibitors. The company focuses on creating therapies for diseases with significant unmet medical needs, particularly in oncology and autoimmune disorders. Carna Biosciences operates through two core segments: a drug discovery business that advances its proprietary pipeline of drug candidates, and a drug discovery support business. The support division provides the global research community with a comprehensive portfolio of products and services, including a wide array of kinase proteins, biochemical and cell-based screening, and profiling services to accelerate pharmaceutical research and development.

Recent filings

Filing Released Lang Actions
内部統制報告書－第21期(2023/01/01－2023/12/31)
Governance Information Classification · 100% confidence The document explicitly states in the header section ("【提出書類】") that it is an "内部統制報告書" (Internal Control Report). It references the legal basis ("金融商品取引法第24条の4の4第1項" - Financial Instruments and Exchange Act Article 24-4-4 Paragraph 1) and details the scope, criteria, and conclusion regarding the assessment of internal controls over financial reporting as of a specific date (2023年12月31日). This content aligns perfectly with the description of an Audit Report / Information (AR), which covers internal or regulatory stress tests and applied accounting principles, although this specific document is an Internal Control Report, which falls under the broader scope of assurance/audit-related documentation not covered by the 10-K or ER. Given the provided definitions, 'AR' (Audit Report / Information) is the closest fit for a formal report detailing internal control effectiveness assessment, distinct from the full annual report (10-K) or a simple earnings release (ER).
2024-03-27 Japanese
確認書
Audit Report / Information Classification · 95% confidence The document is extremely short (588 characters) and appears to be a confirmation statement regarding the appropriateness of the contents of a securities report (有価証券報告書 - Annual Securities Report, which corresponds to a 10-K filing in the US context). The key elements are: '【提出書類】確認書' (Document Submitted: Confirmation), reference to the Financial Instruments and Exchange Act (金融商品取引法), and confirmation by the CEO regarding the appropriateness of the '第21期(自2023年1月1日 至2023年12月31日)の有価証券報告書' (21st Period Securities Report). Since this is a short confirmation document related to the annual report, and not the full 10-K itself, it fits best under the general 'Audit Report / Information' (AR) category, as it relates to the verification/attestation process of the annual filing, or potentially 'Regulatory Filings' (RNS) if AR is too specific for a confirmation letter. Given the context of verifying the annual report's contents, AR is a strong candidate, but since it is a specific confirmation document rather than the audit report itself, and it's a regulatory submission, RNS is often used for miscellaneous regulatory confirmations. However, the content directly addresses the 'Securities Report' (10-K equivalent). Let's re-evaluate the definitions. None perfectly fit a 'Confirmation of 10-K Accuracy' document. Since it is a formal submission confirming the accuracy of the annual filing, and it is not the 10-K (10-K), nor an Audit Report (AR), nor a Proxy (DEF 14A), the most appropriate general regulatory category for a specific confirmation filing that isn't explicitly defined is RNS. If the document were the actual 10-K, it would be 10-K. If it were the auditor's opinion, it would be AR. This is a management certification. Given the options, RNS (Regulatory Filings - fallback) is the safest classification for a specific, short regulatory confirmation document. FY 2023
2024-03-27 Japanese
有価証券報告書－第21期(2023/01/01－2023/12/31)
Annual Report Classification · 100% confidence The document header explicitly identifies itself as an '有価証券報告書' (Annual Securities Report) under the Financial Instruments and Exchange Act, Article 24, Paragraph 1. It covers the fiscal year from January 1, 2023, to December 31, 2023, for Carna Biosciences, Inc. This is the Japanese equivalent of a 10-K annual report. FY 2023
2024-03-27 Japanese
確認書
Report Publication Announcement Classification · 100% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under the Financial Instruments and Exchange Act, specifically confirming the accuracy of a Quarterly Report (Shihanki Hokokusho). It is a regulatory filing required by Japanese law to accompany financial reports, but it is not the report itself. Since it does not fit into specific categories like 10-K or IR, and serves as a formal regulatory submission, it is classified as a Regulatory Filing (RNS).
2023-11-08 Japanese
四半期報告書－第21期第3四半期(2023/07/01－2023/09/30)
Interim / Quarterly Report Classification · 100% confidence The document is a Japanese 'Quarterly Report' (四半期報告書) filed with the Kinki Finance Bureau under the Financial Instruments and Exchange Act. It contains detailed financial statements, management analysis (MDA), and business status updates for the third quarter of the 21st fiscal year (ending September 30, 2023). As it is a comprehensive financial report for an interim period containing actual financial data, it is classified as an Interim/Quarterly Report (IR). 9M 2023
2023-11-08 Japanese
確認書
Report Publication Announcement Classification · 100% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under the Financial Instruments and Exchange Act in Japan. It specifically confirms the accuracy of the contents of the Quarterly Report (Shihanki Hokokusho) for the second quarter of the 21st fiscal period. Since this is a regulatory filing confirming the validity of a report rather than the report itself, and it does not fit into the specific categories like 10-K or IR, it falls under the general regulatory filing category.
2023-08-08 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.